Schering receives EU approval for MRA contrast agent

TriMed Staff | | Health Imaging | Screening
The European Union has cleared Schering AG's contrast agent Gadovist 1.0 for use in magnetic resonance angiography (MRA).

 Gadovist 1.0 has been marketed since 1999 in Europe for MR imaging of the brain and spine.

 MRA is designed as a minimally invasive technology for the detection of vascular disease. It includes stenotic or occlusive changes of the arteries leading to infarction, thrombosis and embolism. Gadovist 1.0 can be used for diagnosis, therapy planning and follow-up of vascular disease.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.